Eastern hepatobilliary surgery hospital
Shanghai, Shanghai Municipality, 200438, China
NCT Number: NCT00849264
This study is working to evaluate the surgical comprehensive treatment for different types of tumor thrombi in the portal vein for hepatocellular carcinoma patients, to establish a standardized, unified, effective therapeutic program.
Looking for future studies?
Notify Me30 year–60 year
All sexes
Interventional
Phase 2
Shanghai, Shanghai Municipality, 200438, China
Primary liver cancer (PLC) has a great tendency to invade portal vein intravascularly, results in the formation of portal vein tumor thrombus (PVTT), which is a crucial factor that can worsen the prognosis of patients with PLC.
In clinical, various treatments have been applied to improve this short-term prognosis, but there was no identical indication for treatment of PLC patients with different PVTT.
The objective of this study is to evaluate the surgical comprehensive treatment for different types of tumor thrombi in the portal vein for hepatocellular carcinoma patients, to establish a standardized, unified, effective therapeutic program.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
15mg/d×14d
Other names: chemotherapy with endostar group
CBP 300mg/d×2d,5-FU 1000mg/d×5d
Other names: treatment with CBP and 5-FU group
CBP 300mg/d×2d,5-FU 1000mg/d×5d ,Endostar 15mg/d×14d
Other names: endostar, CBP and 5-FU group
Time frame: 2010
Time frame: 1,2 and 3 years
Eastern Hepatobiliary Surgery Hospital
Other
a Randomized Controlled Study of Surgical Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01850368
Adenocarcinoma, Carcinoma
Jinju, Gyeongsang-nam-do, South Korea
View Trial DetailsNCT02724475
Adenocarcinoma, Carcinoma
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07062055
Adenocarcinoma, Carcinoma
Jinan, Shandong, China
View Trial DetailsNCT06622031
Adenocarcinoma, Carcinoma
Beijing, None Selected, China
View Trial Details